171 related articles for article (PubMed ID: 20977238)
1. Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
Oster A; Hinsberger S; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
J Med Chem; 2010 Nov; 53(22):8176-86. PubMed ID: 20977238
[TBL] [Abstract][Full Text] [Related]
2. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
[TBL] [Abstract][Full Text] [Related]
4. New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.
Marchais-Oberwinkler S; Wetzel M; Ziegler E; Kruchten P; Werth R; Henn C; Hartmann RW; Frotscher M
J Med Chem; 2011 Jan; 54(2):534-47. PubMed ID: 21189020
[TBL] [Abstract][Full Text] [Related]
5. Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.
Abdelsamie AS; Salah M; Siebenbürger L; Hamed MM; Börger C; van Koppen CJ; Frotscher M; Hartmann RW
Eur J Med Chem; 2019 Sep; 178():93-107. PubMed ID: 31176098
[TBL] [Abstract][Full Text] [Related]
6. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
[TBL] [Abstract][Full Text] [Related]
7. Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.
Wetzel M; Marchais-Oberwinkler S; Perspicace E; Möller G; Adamski J; Hartmann RW
J Med Chem; 2011 Nov; 54(21):7547-57. PubMed ID: 21972996
[TBL] [Abstract][Full Text] [Related]
8. Optimization of hydroxybenzothiazoles as novel potent and selective inhibitors of 17β-HSD1.
Spadaro A; Frotscher M; Hartmann RW
J Med Chem; 2012 Mar; 55(5):2469-73. PubMed ID: 22277094
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.
Starcević S; Brozic P; Turk S; Cesar J; Rizner TL; Gobec S
J Med Chem; 2011 Jan; 54(1):248-61. PubMed ID: 21138273
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a new class of bicyclic substituted hydroxyphenylmethanones as 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors for the treatment of osteoporosis.
Wetzel M; Gargano EM; Hinsberger S; Marchais-Oberwinkler S; Hartmann RW
Eur J Med Chem; 2012 Jan; 47(1):1-17. PubMed ID: 21945251
[TBL] [Abstract][Full Text] [Related]
14. Lead optimization of 17β-HSD1 inhibitors of the (hydroxyphenyl)naphthol sulfonamide type for the treatment of endometriosis.
Henn C; Einspanier A; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
J Med Chem; 2012 Apr; 55(7):3307-18. PubMed ID: 22380653
[TBL] [Abstract][Full Text] [Related]
15. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors.
Xu K; Al-Soud YA; Wetzel M; Hartmann RW; Marchais-Oberwinkler S
Eur J Med Chem; 2011 Dec; 46(12):5978-90. PubMed ID: 22037253
[TBL] [Abstract][Full Text] [Related]
16. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
[TBL] [Abstract][Full Text] [Related]
17. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
19. Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Messinger J; Husen B; Koskimies P; Hirvelä L; Kallio L; Saarenketo P; Thole H
Mol Cell Endocrinol; 2009 Mar; 301(1-2):216-24. PubMed ID: 19014997
[TBL] [Abstract][Full Text] [Related]
20. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]